Moreover, genotyping data from the PTGS2 and CYP2E1 genes, incorporating the haplotype and synergism analytical strategy would facilitate the identification of individuals at high risk of developing lung cancer in future clinical screening. The gene discussed is PTGS2; the disease is lung cancer.